Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Daiichi Sankyo
Biotech
Daiichi-Merck ph. 3 ADC program on pause after patient deaths
Daiichi and Merck’s phase 3 program for I-DXd has been hit with a hold after an unexpected number of deaths occurred.
Gabrielle Masson
Dec 18, 2025 11:22am
ESMO: The ADC 'rollercoaster' rides on with next-gen meds
Oct 21, 2025 3:00am
ESMO: Daiichi, Merck move ovarian cancer ADC toward pivotal test
Oct 20, 2025 10:45am
Daiichi, Merck rev up for accelerated approval filing
Sep 7, 2025 10:45am
Daiichi, Merck pull HER3-DXd filing at FDA
May 29, 2025 9:40am
Roche nets FDA breakthrough label for AI lung cancer CDx test
Apr 29, 2025 2:07pm
